Smith & Nephew PLC
LSE:SN

Watchlist Manager
Smith & Nephew PLC Logo
Smith & Nephew PLC
LSE:SN
Watchlist
Price: 1 272 GBX -1.66% Market Closed
Market Cap: £10.8B

Net Margin

8.3%
Current
Improving
by 2.3%
vs 3-y average of 5.9%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
8.3%
=
Net Income
$491m
/
Revenue
$5.9B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
8.3%
=
Net Income
GBX491m
/
Revenue
$5.9B

Peer Comparison

Country Company Market Cap Net
Margin
UK
Smith & Nephew PLC
LSE:SN
11B GBP
Loading...
US
Abbott Laboratories
NYSE:ABT
192B USD
Loading...
US
Intuitive Surgical Inc
NASDAQ:ISRG
174.6B USD
Loading...
US
Stryker Corp
NYSE:SYK
136.5B USD
Loading...
IE
Medtronic PLC
NYSE:MDT
131.8B USD
Loading...
US
Boston Scientific Corp
NYSE:BSX
112.1B USD
Loading...
US
Becton Dickinson and Co
NYSE:BDX
59.8B USD
Loading...
DE
Siemens Healthineers AG
XETRA:SHL
46B EUR
Loading...
US
IDEXX Laboratories Inc
NASDAQ:IDXX
51.6B USD
Loading...
US
Edwards Lifesciences Corp
NYSE:EW
45.4B USD
Loading...
US
Resmed Inc
NYSE:RMD
39.5B USD
Loading...

Market Distribution

Higher than 96% of companies in United Kingdom
Percentile
96th
Based on 3 670 companies
96th percentile
8.3%
Low
-188 120% — 0%
Typical Range
0% — 0.1%
High
0.1% — 10 443.9%
Distribution Statistics
United Kingdom
Min -188 120%
30th Percentile 0%
Median 0%
70th Percentile 0.1%
Max 10 443.9%

Smith & Nephew PLC
Glance View

Smith & Nephew PLC, a name synonymous with innovation in the medical technology sphere, began its journey in the late 19th century in the quaint city of Kingston upon Hull, England. This humble pharmaceutical shop evolved over time into a global leader in medical devices, driven by a commitment to improve people's quality of life through pioneering healthcare solutions. Today, the company stands as a key player in three core sectors: orthopedics, advanced wound management, and sports medicine. By focusing on these specialized areas, Smith & Nephew has set itself apart, effectively addressing the complex challenges faced by aging populations and a rising demand for minimally invasive treatments. Revenue streams pour in from their innovative products, which cater to both healthcare professionals and patients worldwide. In orthopedics, they make significant headway with implants and instruments used in hip and knee replacements, essential solutions in addressing joint deterioration and injury. Their advanced wound management division tackles issues from chronic wounds to burns, supplying dressings and delivery systems designed for optimal healing. Meanwhile, the sports medicine segment contributes by offering arthroscopy and enabling technologies, crucial for athletic injury prevention and recovery. By maintaining a strong pipeline of research and development initiatives, Smith & Nephew continues to enhance its offerings, pushing the envelope in medical technology and consequently fortifying its financial foundation.

SN Intrinsic Value
1 087.61 GBX
Overvaluation 14%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
8.3%
=
Net Income
$491m
/
Revenue
$5.9B
What is Smith & Nephew PLC's current Net Margin?

The current Net Margin for Smith & Nephew PLC is 8.3%, which is above its 3-year median of 5.9%.

How has Net Margin changed over time?

Over the last 3 years, Smith & Nephew PLC’s Net Margin has decreased from 9.5% to 8.3%. During this period, it reached a low of 4.1% on Jul 1, 2023 and a high of 9.5% on Jul 2, 2022.

Back to Top